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The association between multiple sclerosis and mood changes is well known. It is important to distinguish between primary and secondary mood disorders because the indicated treatments are different, e.g., steroids may be needed to control acute demyelination, or psychotropic medications may cause adverse effects in patients such as ours, who have significant neurologic damage. According to the Poser and Paty criteria, 2 a definitive diagnosis of multiple sclerosis requires two distinct episodes of neurologic deficits with clinical evidence of two separate lesions, or two episodes with clinical evidence of one lesion and paraclinical evidence (including MRI) of another lesion. A single episode can meet criteria if associated with increased cerebrospinal fluid immunoglobulin G (IgG). Other paraclinical evidence in the Poser and Paty criteria includes results of evoked response studies, the hot bath test, and expert urological assessment, although these tests were not pursued in this case. Furthermore, psychopathology associated with multiple sclerosis typically occurs during or immediately after the onset of neurologic symptoms. 1 A clear history of the course of symptoms can further help to differentiate secondary mania from primary mania.
Although it is still possible to make the diagnosis of multiple sclerosis in this patient based on the Poser and Paty criteria by using clinical data alone, MRI is increasingly used to differentiate primary psychiatric symptoms from those secondary to multiple sclerosis. 3 The MRI findings of this patient, however, are consistent with both multiple sclerosis and bipolar disorder.
Eight studies are reported in the literature describing increased rates of either periventricular subcortical gray matter or deep white matter lesions in bipolar disorder. 4 Therefore, white matter abnormalities are associated with both primary and secondary mood disorders. Increased abnormal white matter in bipolar patients has been associated with increased cognitive impairment, and it has been suggested that this subset of bipolar mood disorders results from anomalous myelination. 5 This complicates the differential diagnosis of bipolar disorder from multiple sclerosis and further blurs the boundary between primary and secondary mania.
(SSRIs) in treatment of high-risk patients. 5 We report a case of acute angle-closure glaucoma related to paroxetine use in a patient with mydriasis on examination prior to treatment but who had no personal or family history of glaucoma.
Case report. Ms. A, a 70-year-old widowed Hispanic woman, had required coronary artery bypass surgery several months prior to admission and had experienced progressive decline in functioning associated with depressed mood. Her associated symptoms included a 40-pound (18-kg) weight loss, crying spells, inability to perform activities of daily living, refusal to get out of bed, hopelessness, helplessness, decreased energy, impaired concentration, anhedonia, and marked somatic preoccupation. Ms. A did not use alcohol or illicit intoxicants. She had no previous psychiatric history and no family psychiatric or pertinent medical history. She was taking no medications known to be associated with exacerbation of glaucoma.
Ms. A was initially admitted to the medicine service where she underwent an extensive evaluation of multiple somatic complaints, including chest pain; shortness of breath; difficulty with recent and remote memory; abdominal, bladder, groin, and bilateral leg pain; nausea; and feeling that food was "stuck" in her throat. Assessments included magnetic resonance imaging (MRI) of the entire spine, computed tomography (CT) of the thoracic spine, mammography, bone scan, multiple electrocardiographs both at baseline and during episodes of chest pain, cystoscopy, barium swallow, gastric emptying study, CT and MRI of the head, lumbar puncture, echocardiograph, and extensive laboratory testing. None of these tests indicated abnormalities that explained Ms. A's symptoms. Somatic symptoms secondary to major depression were suspected, and Ms. A was transferred to the inpatient psychiatry service for further treatment.
Ms. A was observed for a 5-day medication-free period after admission to the psychiatry service. She continued to manifest symptoms of major depression and was started on paroxetine 10 mg q.d.; the dose was increased to 20 mg q.d. after 2 days. On the second day of 20-mg-q.d. treatment, the patient complained of severe pain and blurred vision in her left eye. Physical examination revealed a minimally reactive left pupil that was dilated to approximately 7 mm. The right pupil was reactive and measured 3.5 mm. Visual acuity was 20/100 OD, 20/400 OS (had been 20/100 bilaterally at admission); intraocular pressure was 15 mm HG OD, 85 mm HG OS. The patient underwent laser peripheral iridectomy, which decreased intraocular pressure. She was switched to sertraline 50 mg without adverse effect and transferred to the rehabilitation service where she did well, and her depression resolved.
We report here a case of acute angle-closure glaucoma in a patient treated with paroxetine. Acute angle-closure glaucoma has been reported after treatment with several classes of antidepressants, including monoamine oxidase inhibitors, 3 tricyclic antidepressants, [1] [2] [3] [4] [5] and SSRIs (fluoxetine). 7 To our knowledge, this is the first report of acute angle-closure glaucoma associated with paroxetine. The primary action of paroxetine is enhancement of serotonergic neurotransmission through selective inhibition of serotonin reuptake. Additionally, paroxetine exhibits affinity for muscarinic cholinergic receptors, an action which has been associated with mydriasis in vivo 8, 9 ; this effect is dose-dependent and has been observed at doses substantially higher than those used in standard practice. Nonetheless, the correlation between acute angle-closure glaucoma and paroxetine therapy in the present case is of potential clinical significance.
Depression occurs in a substantial number of elderly patients presenting to primary care physicians and to psychiatrists. These patients are at higher risk for intraocular events than the general population, since age is a risk factor for glaucoma. 4 SSRIs have been advocated as the preferred method of treatment for patients considered at high risk for development or exacerbation of glaucoma. 5 This case suggests that even the weak anticholinergic action of paroxetine may be of significance. Alternatively, the fact that a previous case report documented glaucoma associated with fluoxetine 7 suggests that a mechanism other than direct anticholinergic action may be involved. Ophthalmologic monitoring may be beneficial for patients with risk factors for glaucoma during treatment with paroxetine and, indeed, any psychotropic agent with anticholinergic activity. Letters to the Editor months without benefit. He again failed to respond to treatment with paroxetine 40 mg daily for 3 months. Finally, he was treated with fluoxetine 20 mg for 6 weeks and then fluoxetine 40 mg for 3 weeks and improved markedly within days after the dose reached 60 mg daily. He reported feeling "like a changed person" and having confidence in social settings. He had a successful job interview and acquired better paying work. He is able to collaborate with coworkers in a manner inconceivable prior to his treatment. He has been able to attend social gatherings outside the workplace without his usual anxieties. For the first time, he was able to post a note on the Internet. Follow-up has been ongoing for 4 months, and while he continues to have some social anxieties, for example asking a woman out on a date, he views them as being entirely within the range of normal.
While it is possible that a higher dose of paroxetine may also have been effective, it is quite likely that this patient showed a preferential response to fluoxetine. This observation serves to further support the impression that there are efficacy differences among SSRIs.
